Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer

Fiona H Blackhall; Frances A Shepherd

doi:10.1016/j.hoc.2004.06.005

Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer

Hematol Oncol Clin North Am. 2004 Oct;18(5):1121-41, ix. doi: 10.1016/j.hoc.2004.06.005.

Authors

Fiona H Blackhall¹, Frances A Shepherd

Affiliation

¹ Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX England, UK.

PMID: 15474338
DOI: 10.1016/j.hoc.2004.06.005

Abstract

Angiogenesis is believed to play a critical role in cancer; however, antiangiogenic therapy has not been demonstrated to improve the survival of patients who have lung cancer. In this article, the evidence that supports a role for angiogenesis in the pathogenesis of lung cancer, trials of antiangiogenic agents in lung cancer performed to date, and the lessons learned from these studies are discussed.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Carcinoma, Non-Small-Cell Lung / blood supply
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Small Cell / blood supply
Carcinoma, Small Cell / drug therapy*
Clinical Trials as Topic
Humans
Lung Neoplasms / blood supply
Lung Neoplasms / drug therapy*
Neovascularization, Pathologic / prevention & control
Protease Inhibitors / therapeutic use
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Protease Inhibitors
Vascular Endothelial Growth Factor A